Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ravi Tripathi, Abiodun Anifowose, Wen Lu, Xiaoxiao Yang & Binghe Wang. (2022) Upregulation of p53 through induction of MDM2 degradation: improved potency through the introduction of an alkylketone sidechain on the anthraquinone core. Journal of Enzyme Inhibition and Medicinal Chemistry 37:1, pages 2370-2381.
Read now
Read now
Christian Klein, Marina Bacac, Pablo Umana & Günter Fingerle-Rowson. (2017) Combination therapy with the type II anti-CD20 antibody obinutuzumab. Expert Opinion on Investigational Drugs 26:10, pages 1145-1162.
Read now
Read now
Anaïs Pujals, Loëtitia Favre, Philippe Gaulard & Joëlle Wiels. (2015) Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment. Blood and Lymphatic Cancer: Targets and Therapy 5, pages 93-100.
Read now
Read now
Susan K Peirce & Harry W Findley. (2010) Targeting the MDM2–p53 interaction as a therapeutic strategy for the treatment of cancer. Cell Health and Cytoskeleton 2, pages 49-58.
Read now
Read now
Alyssa Bouska, Tamara Lushnikova, Silvia Plaza & Christine M. Eischen. (2008) Mdm2 Promotes Genetic Instability and Transformation Independent of p53 . Molecular and Cellular Biology 28:15, pages 4862-4874.
Read now
Read now
Articles from other publishers (54)
Sylvia Yao Sun & Aimee Crago. (2023) MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors. Journal of Clinical Medicine 12:11, pages 3638.
Crossref
Crossref
Norman Salomao, Nabih Maslah, Anouk Giulianelli, Louis Drevon, Lorea Aguinaga, Xiaolian Gu, Bruno Cassinat, Stephane Giraudier, Pierre Fenaux & Robin Fahraeus. (2022)
Reduced murine double minute 2 and
4
protein, but not
messenger RNA
, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia
. British Journal of Haematology 201:2, pages 234-248.
Crossref
Crossref
Marcin Herok, Bartosz Wawrzynow, Marta J. Maluszek, Maciej B. Olszewski, Alicja Zylicz & Maciej Zylicz. (2021) Chemotherapy of HER2- and MDM2-Enriched Breast Cancer Subtypes Induces Homologous Recombination DNA Repair and Chemoresistance. Cancers 13:18, pages 4501.
Crossref
Crossref
Sivakumar Vadivel Gnanasundram, Laurence Malbert-Colas, Sa Chen, Leila Fusée, Chrysoula Daskalogianni, Petr Muller, Norman Salomao & Robin Fåhraeus. (2020) MDM2’s dual mRNA binding domains co-ordinate its oncogenic and tumour suppressor activities. Nucleic Acids Research 48:12, pages 6775-6787.
Crossref
Crossref
Iris Kamer, Inbal Daniel-Meshulam, Oranit Zadok, Elizabeta Bab-Dinitz, Gili Perry, Rotem Feniger-Barish, Marina Perelman, Iris Barshack, Alon Ben-Nun, Amir Onn & Jair Bar. (2020) Stromal-MDM2 Promotes Lung Cancer Cell Invasion through Tumor–Host Feedback Signaling. Molecular Cancer Research 18:6, pages 926-937.
Crossref
Crossref
Huafeng Wang, Dandan Zhao, Le Xuan Nguyen, Herman Wu, Ling Li, Dan Dong, Estelle Troadec, Yinghui Zhu, Dinh Hoa Hoang, Anthony S. Stein, Monzr Al Malki, Ibrahim Aldoss, Allen Lin, Lucy Y. Ghoda, Tinisha McDonald, Flavia Pichiorri, Nadia Carlesso, Ya-Huei Kuo, Bin Zhang, Jie Jin & Guido Marcucci. (2019) Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia 34:1, pages 75-86.
Crossref
Crossref
Scott Bang, Sandeep Kaur & Manabu Kurokawa. (2019) Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway. International Journal of Molecular Sciences 21:1, pages 261.
Crossref
Crossref
Zhengyi Cao, Junhui Xue, Yuning Cheng, Jiyin Wang, Yujuan Liu, Hui Li, Wei Jiang, Gang Li, Yaoting Gui & Xiaowei Zhang. (2019) MDM2 promotes genome instability by ubiquitinating the transcription factor HBP1. Oncogene 38:24, pages 4835-4855.
Crossref
Crossref
Scott Bang, Heeruk C. Bhatt, Yun Yue Chen & Manabu Kurokawa. 2018. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
3021
3028
.
Dong Min Kim, Seung-Hyun Choi, Young Il Yeom, Sang-Hyun Min & Il-Chul Kim. (2016) Genome-scale functional analysis of the human genes modulating p53 activity by regulating MDM2 expression in a p53-independent manner. Biochemical and Biophysical Research Communications 478:2, pages 976-981.
Crossref
Crossref
M F Riley, M J You, A S Multani & G Lozano. (2015) Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma. Oncogene 35:3, pages 358-365.
Crossref
Crossref
Scott Bang, Heeruk C. Bhatt, Yun Yue Chen & Manabu Kurokawa. 2016. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
1
8
.
Ryan Clanton, David Saucier, John Ford & Gamal Akabani. (2015) Microbial influences on hormesis, oncogenesis, and therapy: A review of the literature. Environmental Research 142, pages 239-256.
Crossref
Crossref
Dana Thomasova, Hauke A. Bruns, Victoria Kretschmer, Martrez Ebrahim, Simone Romoli, Helen Liapis, Ahmed M. Kotb, Nicole Endlich & Hans-Joachim Anders. (2015) Murine Double Minute-2 Prevents p53-Overactivation-Related Cell Death (Podoptosis) of Podocytes. Journal of the American Society of Nephrology 26:7, pages 1513-1523.
Crossref
Crossref
Sara M. Reed, Jussara Hagen, Viviane P. Muniz, Timothy R. Rosean, Nick Borcherding, Sebastian Sciegienka, J. Adam Goeken, Paul W. Naumann, Weizhou Zhang, Van S. Tompkins, Siegfried Janz, David K. Meyerholz & Dawn E. Quelle. (2014) NIAM-Deficient Mice Are Predisposed to the Development of Proliferative Lesions including B-Cell Lymphomas. PLoS ONE 9:11, pages e112126.
Crossref
Crossref
Ruiwen Zhang & Subhasree Nag. 2014. Pharma-Nutrition. Pharma-Nutrition
305
342
.
Burcu Anil, Christiane Riedinger, Jane A. Endicott & Martin E. M. Noble. (2013) The structure of an MDM2–Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. Acta Crystallographica Section D Biological Crystallography 69:8, pages 1358-1366.
Crossref
Crossref
V. Ribrag, V. Camara-Clayette, J. Bosq & Y. Vasstezky. (2012) Lymphome de Burkitt. EMC - Hématologie 7:4, pages 1-11.
Crossref
Crossref
M W Gramling & C M Eischen. (2012) Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis. Cell Death & Differentiation 19:7, pages 1220-1227.
Crossref
Crossref
Beng Hooi Phang, Hui Wan Chua, Huihua Li, Yeh Ching Linn & Kanaga Sabapathy. (2011) Characterization of Novel and Uncharacterized p53 SNPs in the Chinese Population – Intron 2 SNP Co-Segregates with the Common Codon 72 Polymorphism. PLoS ONE 6:1, pages e15320.
Crossref
Crossref
Alyssa Bouska & Christine M. Eischen. (2009) Mdm2 Affects Genome Stability Independent of p53. Cancer Research 69:5, pages 1697-1701.
Crossref
Crossref
Sandra Quijano, Antonio López, Ana Rasillo, José María Sayagués, Susana Barrena, Maria Luz Sánchez, Cristina Teodosio, Pilar Giraldo, Manuel Giralt, M. Carmen Pérez, Mercedes Romero, Luis Perdiguer & Alberto Orfao. (2007) Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B‐cells in chronic lymphocytic leukemia. Cytometry Part B: Clinical Cytometry 74B:3, pages 139-149.
Crossref
Crossref
P Wang, T Lushnikova, J Odvody, T C Greiner, S N Jones & C M Eischen. (2007) Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene 27:11, pages 1590-1598.
Crossref
Crossref
Beng Hooi Phang, Yeh Ching Linn, Huihua Li & Kanaga Sabapathy. (2008) MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. European Journal of Cancer 44:5, pages 760-766.
Crossref
Crossref
Chris Saddler, Peter Ouillette, Lisa Kujawski, Sanjeev Shangary, Moshe Talpaz, Mark Kaminski, Harry Erba, Kerby Shedden, Shaomeng Wang & Sami N. Malek. (2008) Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111:3, pages 1584-1593.
Crossref
Crossref
Christian Klein & Lyubomir T. Vassilev. 2008. Checkpoint Responses in Cancer Therapy. Checkpoint Responses in Cancer Therapy
19
56
.
Onoshua Lahiri, Scott Harris, Graham Packham & Melanie Howell. (2007) p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics 179:1, pages 36-44.
Crossref
Crossref
Mu-Shui Dai, Yetao Jin, Jayme R. Gallegos & Hua Lu. (2006) Balance of Yin and Yang: Ubiquitylation-Mediated Regulation of p53 and c-Myc. Neoplasia 8:8, pages 630-644.
Crossref
Crossref
Mu-Shui Dai, Dingding Shi, Yetao Jin, Xiao-Xin Sun, Yanping Zhang, Steven R. Grossman & Hua Lu. (2006) Regulation of the MDM2-p53 Pathway by Ribosomal Protein L11 Involves a Post-ubiquitination Mechanism. Journal of Biological Chemistry 281:34, pages 24304-24313.
Crossref
Crossref
Matthieu Bui Nguyen Binh, Xavier Sastre Garau, Louis Guillou, Alain Aurias & Jean-Michel Coindre. (2006) Reproducibility of MDM2 and CDK4 Staining in Soft Tissue Tumors. American Journal of Clinical Pathology 125:5, pages 693-697.
Crossref
Crossref
Kirsteen H. Maclean & John L. Cleveland. 2010. Childhood Leukemias. Childhood Leukemias
339
361
.
Ratchada Cressey, Sarunya Pimpa, Waragorn Tontrong, Onusa Watananupong & Nirush Leartprasertsuke. (2006) Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression. Cancer Letters 233:2, pages 232-239.
Crossref
Crossref
Levi J. Beverly, Dean W. Felsher & Anthony J. Capobianco. (2005) Suppression of p53 by Notch in Lymphomagenesis: Implications for Initiation and Regression. Cancer Research 65:16, pages 7159-7168.
Crossref
Crossref
A J Davies, A M Lee, C Taylor, A J Clear, L K Goff, S Iqbal, D Cuthbert-Heavens, M Calaminici, A J Norton, T A Lister & J Fitzgibbon. (2005) A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 19:8, pages 1459-1465.
Crossref
Crossref
Irene M. GhobrialDaniel J. McCormickScott H. KaufmannAlexey A. LeontovichDavid A. LoegeringNga T. DaiKelly L. KrajnikMary J. StensonMona F. MelhemAnne J. NovakStephen M. AnsellThomas E. Witzig. (2005) Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood 105:9, pages 3722-3730.
Crossref
Crossref
Jodi R. Alt, Alyssa Bouska, Mario R. Fernandez, Ronald L. Cerny, Hua Xiao & Christine M. Eischen. (2005) Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair. Journal of Biological Chemistry 280:19, pages 18771-18781.
Crossref
Crossref
Amandine H L Truong, David Cervi, Jane Lee & Yaacov Ben-David. (2004) Direct transcriptional regulation of MDM2 by Fli-1. Oncogene 24:6, pages 962-969.
Crossref
Crossref
Xinwei Zhang, Min Wang, Chunlin Zhou, Sen Chen & Jianxiang Wang. (2005) The expression of iASPP in acute leukemias. Leukemia Research 29:2, pages 179-183.
Crossref
Crossref
Christine M Eischen, Jodi R Alt & Peng Wang. (2004) Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development. Oncogene 23:55, pages 8931-8940.
Crossref
Crossref
Stanley R. Riddell & Philip D. Greenberg. 2003. Thomas' Hematopoietic Cell Transplantation. Thomas' Hematopoietic Cell Transplantation
380
404
.
Albert DeLeo, Susanne Beckebaum & Vito Cicinnati. 2003. Tumor Antigens Recognized by T Cells and Antibodies. Tumor Antigens Recognized by T Cells and Antibodies
3
19
.
Kei‐ji Sugimoto, Norihiko Kawamata, Sakura Sakajiri & Kazuo Oshimi. (2005)
Molecular Analysis of Oncogenes,
ras
Family Genes (
N‐ras, K‐ras, H‐ras
),
myc
Family Genes (
c‐myc, N‐myc
) and
mdm2
in Natural Killer Cell Neoplasms
. Japanese Journal of Cancer Research 93:11, pages 1270-1277.
Crossref
Crossref
Alex I. Zaika, Neda Slade, Susan H. Erster, Christine Sansome, Troy W. Joseph, Michael Pearl, Eva Chalas & Ute M. Moll. (2002) ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors. The Journal of Experimental Medicine 196:6, pages 765-780.
Crossref
Crossref
Troy R. Shirangi, Alex Zaika & Ute M. Moll. (2002) Nuclear degradation of p53 occurs during down‐regulation of the p53 response after DNA damage. The FASEB Journal 16:3, pages 420-422.
Crossref
Crossref
Sharon L. BarransIan CarterRoger G. OwenFaith E. DaviesRussell D. PatmoreAndrew P. HaynesGareth J. MorganAndrew S. Jack. (2002) Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99:4, pages 1136-1143.
Crossref
Crossref
Isabella A. Atencio, Jenny B. Avanzini, Duane Johnson, Saskia Neuteboom, Mei-Ting Vaillancourt, Loretta L. Nielsen, Gerry Hajian, Suganto Sutjipto, Barry J. Sugarman, Jennifer Philopena, Diane L. McAllister, Josefina C. Beltran, Margarita Nodelman, Murali Ramachandra & Ken N. Wills. (2001) Enhanced Apoptotic Activity of a p53 Variant in Tumors Resistant to Wild-Type p53 Treatment. Molecular Therapy 4:1, pages 5-12.
Crossref
Crossref
Yu-ling Wu, John W Mehew, Caroline A Heckman, Magdalena Arcinas & Linda M Boxer. (2001) Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20:2, pages 240-251.
Crossref
Crossref
Audrey S. BaurPhil ShawNathalie BurriFrançoise DelacrétazFred T. BosmanPascal Chaubert. (1999) Frequent Methylation Silencing of p15INK4b(MTS2) and p16INK4a (MTS1) in B-Cell and T-Cell Lymphomas. Blood 94:5, pages 1773-1781.
Crossref
Crossref
Audrey S. BaurPhil ShawNathalie BurriFrançoise DelacrétazFred T. BosmanPascal Chaubert. (1999) Frequent Methylation Silencing of p15INK4b(MTS2) and p16INK4a (MTS1) in B-Cell and T-Cell Lymphomas. Blood 94:5, pages 1773-1781.
Crossref
Crossref
Peiqing SunPing DongKang DaiGregory J. HannonDavid Beach. (1998) p53-Independent Role of MDM2 in TGF-β1 Resistance. Science 282:5397, pages 2270-2272.
Crossref
Crossref
Trenna Sutcliffe, Loning Fu, Jacinth Abraham, Homayoun Vaziri & Samuel Benchimol. (1998) A Functional Wild-Type p53 Gene Is Expressed in Human Acute Myeloid Leukemia Cell Lines. Blood 92:8, pages 2977-2979.
Crossref
Crossref
James W. Wilson, Catherine Booth & Christopher S. PottenMaureen Murphy & Arnold J. Levine. 1999. Apoptosis Genes. Apoptosis Genes
5
35
.
Seymour GarteSeymour Garte. 1998. Genetic Susceptibility to Cancer. Genetic Susceptibility to Cancer
31
49
.
E. Montserrat, F. Bosch & C. Rozman. (1997) B-cell chronic lymphocytic leukemia: Recent progress in biology, diagnosis, and therapy. Annals of Oncology 8, pages S93-S101.
Crossref
Crossref